These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10537326)
1. Oral cancer chemotherapy: the promise and the pitfalls. McLeod HL; Evans WE Clin Cancer Res; 1999 Oct; 5(10):2669-71. PubMed ID: 10537326 [No Abstract] [Full Text] [Related]
2. Promises and pitfalls of oral cancer chemotherapy. Ergolin MJ Clin Adv Hematol Oncol; 2009 Feb; 7(2):S8-10. PubMed ID: 19391311 [No Abstract] [Full Text] [Related]
4. The challenges of oral agents as antineoplastic treatments. Given BA; Spoelstra SL; Grant M Semin Oncol Nurs; 2011 May; 27(2):93-103. PubMed ID: 21514479 [TBL] [Abstract][Full Text] [Related]
5. There's many a slip twixt cup and lip: adherence issues in cancer therapy. Fallowfield L Nat Clin Pract Oncol; 2008 Mar; 5(3):118-9. PubMed ID: 18212767 [No Abstract] [Full Text] [Related]
6. Assessment and measurement of adherence to oral antineoplastic agents. Spoelstra SL; Given CW Semin Oncol Nurs; 2011 May; 27(2):116-32. PubMed ID: 21514481 [TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Navarro RP; Morrow T; Baran R Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298 [TBL] [Abstract][Full Text] [Related]
8. Nursing strategies for patients on oral chemotherapy. Hollywood E; Semple D Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):37-9; discussion 40. PubMed ID: 11219976 [TBL] [Abstract][Full Text] [Related]
9. Challenges of oral medications in patients with advanced breast cancer. Palmieri FM; Barton DL Semin Oncol Nurs; 2007 Nov; 23(4 Suppl 2):S17-22. PubMed ID: 18054678 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659 [TBL] [Abstract][Full Text] [Related]
13. Oral agents in cancer treatment: the context for adherence. Barton D Semin Oncol Nurs; 2011 May; 27(2):104-15. PubMed ID: 21514480 [TBL] [Abstract][Full Text] [Related]
14. Patient adherence with oral oncolytic therapies. Vioral A; Leslie M; Best R; Somerville D Semin Oncol Nurs; 2014 Aug; 30(3):190-9. PubMed ID: 25085031 [TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies. Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer. Olver I; Keefe D; Myers M Intern Med J; 2005 Jul; 35(7):405-8. PubMed ID: 15958110 [TBL] [Abstract][Full Text] [Related]